Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04838301
PHASE2

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Sponsor: University of Arizona

View on ClinicalTrials.gov

Summary

A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.

Official title: Safety and Efficacy of Allopregnanolone (Allo) as a Regenerative Therapeutic for Alzheimer's Disease: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Clinical Trial

Key Details

Gender

All

Age Range

55 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2023-08-15

Completion Date

2027-03-18

Last Updated

2026-03-13

Healthy Volunteers

No

Interventions

DRUG

Allopregnanolone

Allopregnanolone 4mg IV via 30-minute infusion, once per week.

OTHER

Placebo

Normal saline solution IV via 30-minute infusion, once per week

Locations (10)

Perseverance Research Center

Scottsdale, Arizona, United States

University of Arizona / Clinical & Translational Sciences Research Center

Tucson, Arizona, United States

ATP Clinical Research

Costa Mesa, California, United States

Wake Research-PRI, LLC

Los Alamitos, California, United States

Syrentis Clinical Research

Santa Ana, California, United States

Optimus U Corporation

Miami, Florida, United States

Miami Jewish Health

Miami, Florida, United States

Combined Research Orlando

Orlando, Florida, United States

Conquest Research

Winter Park, Florida, United States

MedVadis Research

Waltham, Massachusetts, United States